Table 4.

Outcomes for preclinical models of treatment or prevention of GVHD

Study	Model	Survival (I vs C)	GVHD Clinical score (I vs C)	Skin score (I vs C)	Histology (I vs C)
[23]	Treatment	16 vs 10 d (p < 0.01)	2.8 vs 3.5 at 10 d (p < 0.01)a	Severe, 60% vs 89%	Large boweld: 7 vs 12 (p < 0.01) at 6 d Liver/small bowel: no difference at 6 d
[24]	Treatment	48 vs 34 d (p NR)	3 vs 6 at 50 d (p NR)b	2.5 vs 3.5 at 50 d (p NR)c	Liver, lung, skin: Improved Fibrosis: Liver: 5% vs 20% (p < 0.05) Lung: 6% vs 15% (p < 0.05) Skin: 30% vs 75% (p < 0.01)
[25]	Prevention	25 vs 22 d (p < 0.05)	4 vs 8 at 24 d (p < 0.05)e	NR	NR
[26]	Prevention	60 vs 36 d (p < 0.01)	2 vs 10 at 56 days (p < 0.001)f	NR	Liver, large intestine, skin: Improved

^aClinical score at 10 days: 0 (good) to 2 (poor) for weight loss, posture, activity, fur texture and skin integrity and summed for a total score of 0–10

^bClinical score: Skin, body weight and hunch. Maximum total score = 7.9

^cSkin score: Minimum score 0; maximum score 3.9

^dHistology score: Maximum total score of 28 for the large bowel and small bowel, and 40 for the liver

^eMean combined disease activity index: Grade 0/1/2 assigned to weight loss, posture, activity, fur texture, skin integrity and paleness. Maximum total score = 1

^fClinical score: Grade 0/1/2 assigned to weight loss, posture, activity, fur texture and skin integrity. Maximum total score = 10